Oxcarbazepine
- Generic Name
- Oxcarbazepine
- Brand Names
- Oxtellar, Trileptal
- Drug Type
- Small Molecule
- Chemical Formula
- C15H12N2O2
- CAS Number
- 28721-07-5
- Unique Ingredient Identifier
- VZI5B1W380
- Background
Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000. It is a structural derivative of carbamazepine and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exists as a racemate in the blood - a pro-drug of the more active...
- Indication
In the United States, oxcarbazepine is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures.
...
- Associated Conditions
- Partial-Onset Seizures
- Associated Therapies
- Monotherapy
The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States.
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 55
- Registration Number
- NCT00154323
The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2011-11-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 50
- Registration Number
- NCT00154362
The Effect of Oxcarbazepine in the Treatment of Agitation / Aggression in Dementia (OBAD)
- Conditions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2007-03-21
- Lead Sponsor
- Sykehuset Innlandet HF
- Target Recruit Count
- 100
- Registration Number
- NCT00145691
- Locations
- 🇳🇴
Sykehuset Innlandet HF, Reinsvoll, Oppland, Norway
Study of Efficacy of Oxcarbazepine in Therapy of Bronchial Asthma
- Conditions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2009-02-19
- Lead Sponsor
- Centre of Chinese Medicine, Georgia
- Target Recruit Count
- 55
- Registration Number
- NCT00142025
Pediatric Epilepsy Study
- Conditions
- First Posted Date
- 2003-01-01
- Last Posted Date
- 2011-11-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 132
- Registration Number
- NCT00050934
- Locations
- 🇲🇽
Novartis, Mexico City, Mexico
🇧🇷Brigadeiro Hospital, Sao Paulo - SP, Brazil
Pediatric Epilepsy Study
- Conditions
- First Posted Date
- 2003-01-01
- Last Posted Date
- 2011-11-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 94
- Registration Number
- NCT00050947
- Locations
- 🇲🇽
Novartis, Mexico City, Mexico
🇧🇷Brigadeiro Hospital, Sao Paulo - SP, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.